Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling

Journal of Molecular and Cellular Cardiology

Volumn 89, Issue , 2015, Pages 87-97

  Lu, Chen ^a   Wang, Xiaohui ^a   Ha, Tuanzhu ^a   Hu, Yuanping ^a   Liu, Li ^b   Zhang, Xia ^a   Yu, Honghui ^c   Miao, Jonathan ^a   Kao, Race ^a   Kalbfleisch, John ^a   Williams, David ^a   Li, Chuanfu ^a  

^a East Tennessee State University   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiogenesis; MicroRNA 130a; Myocardial infarction; PI3K Akt signaling; PTEN

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; COLLAGEN; GELATINASE A; MICRORNA; MICRORNA 130A; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; LIGAND; MIRN130 MICRORNA, HUMAN; MIRN130 MICRORNA, MOUSE; TOLL LIKE RECEPTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; HEART DISEASE; HEART EJECTION FRACTION; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CELL MOTION; COMPLICATION; ENZYMOLOGY; GENETIC TRANSFECTION; HEART; LENTIVIRINAE; METABOLISM; MICROVASCULATURE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CELL MOVEMENT; COLLAGEN; ENZYME ACTIVATION; HEART; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; LENTIVIRUS; LIGANDS; MALE; MATRIX METALLOPROTEINASE 2; MICE, INBRED C57BL; MICRORNAS; MICROVESSELS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84952663236     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.10.011     Document Type: Article

References (40)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart Disease and Stroke Statistics - 2011 Update. Circulation 2011, 123:e18-e209.
2. Fiedler J., Thum T. MicroRNAs in myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2013, 33:201-205.
3. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90:1250.
4. Oudit G.Y., Penninger J.M. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc. Res. 2009, 82:250-260.
5. Ha T., Hu Y., Liu L., Lu C., McMullen J.R., Shioi T., et al. TLR2 ligands induce cardioprotection against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc. Res. 2010, 87:694-703.
6. Ha T., Hua F., Liu X., Ma J., McMullen J.R., Shioi T., et al. Lipopolysaccharide-induced myocardial protection against ischemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovascr Res 2008, 78:546-553.
7. Cao Z., Ren D., Ha T., Liu L., Wang X., Kalbfleisch J., et al. CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling. Biochim. Biophys. Acta 1832, 2013:96-104.
8. Oudit G.Y., Sun H., Benoit-Gilles K., Crackower M.A., Penninger J.M., Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 2004, 37:449-471.
9. Keyes K.T., Xu J., Long B., Zhang C., Hu Z., Ye Y. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am J Physiol Heart Circ Physiol 2010, 298:H1198-H1208.
10. Schroen B., Heymans S. MicroRNAs and beyond: the heart reveals its treasures. Hypertension 2009, 54:1189-1194.
11. van Rooij E., Marshall W.S., Olson E.N. Toward MicroRNA-based therapeutics for heart disease: the sense in antisense. Circ. Res. 2008, 103:919-928.
12. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713.
13. Ren X.P., Wu J., Wang X., Sartor M.A., Qian J., Jones K., et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009, 119:2357-2366.
14. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:984.
15. Wang X., Zhang X., Ren X.P., Chen J., Liu H., Yang J., et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardial injury. Circulation 2010, 122:1308-1318.
16. van Rooij E., Olson E.N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Invest. 2007, 117:2369-2376.
17. Yang L., Li N., Wang H., Jia X., Wang X., Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol. Rep. 2012, 28:592-600.
18. Chen Y., Gorski D.H. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008, 111:1217-1226.
19. Wang X., Ha T., Liu L., Zou J., Zhang X., Kalbfleisch J., et al. Increased expression of microRNA-164a decreases myocardial ischemia/reperfusion injury. Cardiovasc. Res. 2013, 97:432-442.
20. Wang X., Ha T., Zou J., Ren D., Liu L., Zhang X., et al. MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6. Cardiovasc. Res. 2014, 102:385-395.
21. Lu C., Ren D., Wang X., Ha T., Liu L., Lee E.J., et al. Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury. Biochim. Biophys. Acta 1842, 2014:22-31.
22. Hua F., Ha T., Ma J., Li Y., Kelley J., Gao X., et al. Protection against myocardial ischemia/reperfusion injury in TLR4 deficient mice is mediated through a phosphoinositide 3-kinase dependent mechanism. J. Immunol. 2007, 178:7317-7324.
23. Li Y., Ha T., Gao X., Kelley J., Williams D.L., Browder I.W., et al. NK-kB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 2004, 287:H1712-H1720.
24. Gao M., Ha T., Zhang X., Liu L., Wang X., Kelley J., et al. Toll-like receptor 3 plays a central role in cardiac dysfunction during polymicrobial sepsis. Crit. Care Med. 2012, 40:2390-2399.
25. Tse H.F., Kwong Y.L., Chan J.K., Lo G., Ho C.L., Lau C.P. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mono-nuclear cell implantation. Lancet 2003, 361:47-49.
26. Goetze S., Bungenstock A., Czupalla C., Eilers F., Stawowy P., Kintscher U., et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 2002, 40:748-754.
27. Matsumura S., Iwanaga S., Mochizuki S., Okamoto H., Ogawa S., Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J. Clin. Invest. 2005, 115:599-609.
28. Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., et al. MicroRNA expression in response to murine myocardial infarction: niR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82:21-29.
29. Abbate A., Bussani R., Amin M.S., Vetrovec G.W., Baldi A. Acuta myocardial infarction and heart failure: role of apoptosis. Int. J. Biochem. Cell Biol. 2006, 38:1834-1840.
30. Herrmann J.L., Beham A.W., Sarkiss M., Chiao P.J., Rands M.T., Bruckheimer E.M., et al. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp. Cell Res. 1997, 237:101-109.
31. Tammela T., Enholm B., Alitalo K., Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc. Res. 2005, 65:550-563.
32. Rhoads K., Arderiu G., Charboneau A., Hansen S.L., Hoffman W., Boudreau N. A role for Hox A5 in regulating angiogenesis and vascular patterning. Lymphat. Res. Biol. 2005, 3:240-252.
33. Karar J., Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 2011, 4:51.
34. van der Laan A.M., Piek J.J., van Royen N. Targeting antiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol 2009, 6:515-523.
35. Olivetti G., Abbi R., Quaini F., Krajewski S., Cheng W., Nitahara J.A., et al. Apoptosis in the failing human heart. N. Engl. J. Med. 1997, 336:1131-1141.
36. Abbate A., Morales C., De Falco M., Fedele V., Biondi Zaccai G.G., Santini D., et al. Ischemia and apoptosis in an animal model of permanent infarct-related artery occlusion. Int. J. Cardiol. 2007, 121:109-111.
37. Chandrashekhar Y., Sen S., Anway R., Shuros A., Anand I. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J. Am. Coll. Cardiol. 2004, 43:295-301.
38. Hochhauser E., Cheporko Y., Yasovich N., Pinchas L., Offen D., Barhum Y., et al. Bax deficiency reduces infarct size and improves long-term function after myocardial infarction. Cell Biochem. Biophys. 2007, 47:11-20.
39. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 285:1132-1136.
40. Matsui T., Tao J., del Monte F., Lee K.H., Li L., Picard M., et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001, 104:330-335.